How New Filspari Reviews And Price Targets Are Rewriting The Story For Travere Therapeutics (TVTX)

Travere Therapeutics’ updated fair value estimate of $42.36, up from $41.64, reflects fresh Street research that is reworking revenue growth expectations and the risk profile around the Filspari ...

AbbVie: Dominating Immunology While Building Oncology Upside

The total net revenues of AbbVie's Rinvoq and Skyrizi were about $25.87 billion in 2025, up 46.2% from 2024. Read why ABBV ...
The Baltimore Sun

Submit Letter to the Editor

The Sun welcomes comments from readers via letters to the editor. All comments become the property of The Sun, which reserves the right to edit them. To submit a letter to the editor, use the form ...